- Home
- SHMD vs CUE Comparison
SHMD vs CUE Comparison
Compare SHMD & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SHMD | CUE |
|---|---|---|
| Founded | 1864 | 2014 |
| Country | Germany | United States |
| Employees | N/A | 29 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.0M | 26.0M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | SHMD | CUE |
|---|---|---|
| Price | $6.58 | $0.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 799.0K | ★ 804.6K |
| Earning Date | 05-15-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $2.00 | $0.23 |
| 52 Week High | $10.65 | $1.05 |
Technical Indicators
Market Signals| Indicator | SHMD | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 46.42 | 38.03 |
| Support Level | $2.36 | $0.23 |
| Resistance Level | $6.70 | $0.35 |
| Average True Range (ATR) | 0.78 | 0.03 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 29.65 | 14.61 |
Price Performance
Historical ComparisonAbout SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.